Identification of the oxidative and conjugative enzymes involved in the biotransformation of brivanib

Drug Metabolism and Disposition

Volumn 40, Issue 1, 2012, Pages 219-226

  Gong, Jiachang ^a   Gan, Jinping ^a   Iyer, Ramaswamy A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIMETHYLAMINO 5,6 DIHYDROXYTETRALIN; BRIVANIB; BRIVANIB ALANINATE; CARBOXYLESTERASE; COMPLEMENTARY DNA; CONJUGATIVE ENZYME; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DASATINIB; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLIZING ENZYME; FURAFYLLINE; KETOCONAZOLE; MONTELUKAST; ORPHENADRINE; OXIDOREDUCTASE; QUINIDINE; SULFAPHENAZOLE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A3; SULFOTRANSFERASE 1B1; SULFOTRANSFERASE 1E1; SULFOTRANSFERASE 2A1; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG HYDROXYLATION; DRUG OXIDATION; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SULFATION;

ALANINE; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; CYTOSOL; HUMANS; OXIDATION-REDUCTION; SULFOTRANSFERASES; TRIAZINES;

EID: 84455174541     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.042457     Document Type: Article

References (41)

1. Ayers M, Fargnoli J, Lewin A, Wu Q, and Platero JS (2007) Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/ FGFR-1 antagonist. Cancer Res 67:6899-6906. (Pubitemid 47105537)
2. Baka S, Clamp AR, and Jayson GC (2006) A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 10:867-876. (Pubitemid 44816749)
3. Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, et al. (2006) Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1Hindol- 5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 49:2143-2146.
4. Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R Sr, Kukral DW, Fura A, et al. (2005) Design, synthesis, and evaluation of orally active 4-(2,4- difluoro-5-(methoxycarbamoyl)phenylamino) pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. J Med Chem 48:3991-4008. (Pubitemid 40800608)
5. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, et al. (2008) Discovery of brivanib alaninate ((S)-((R)-1-(4-(4- fluoro-2-methyl-1H-indol-5- yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy) propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 51:1976-1980. (Pubitemid 351438880)
6. Carmeliet P and Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257.
7. Cross MJ and Claesson-Welsh L (2001) FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22:201-207. (Pubitemid 32244307)
8. Dempke WC and Zippel R (2010) Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor. Anticancer Res 30:4477-4483.
9. Diaz-Padilla I and Siu LL (2011) Brivanib alaninate for cancer. Expert Opin Investig Drugs 20:577-586.
10. Ellis LM and Fidler IJ (1996) Angiogenesis and metastasis. Eur J Cancer 32A:2451-2460.
11. Fujita K, Nagata K, Yamazaki T, Watanabe E, Shimada M, and Yamazoe Y (1999) Enzymatic characterization of human cytosolic sulfotransferases; identification of ST1B2 as a thyroid hormone sulfotransferase. Biol Pharm Bull 22:446-452. (Pubitemid 29252215)
12. Fujiyama N, Miura M, Kato S, Sone T, Isobe M, and Satoh S (2010) Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos 38:2210-2217.
13. Fung EN, Zheng N, Arnold ME, and Zeng J (2010) Effective screening approach to select esterase inhibitors used for stabilizing ester-containing prodrugs analyzed by LC-MS/MS. Bioanalysis 2:733-743.
14. Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, and McManus ME (2006) Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90:5-22. (Pubitemid 43264722)
15. Gelboin HV and Krausz K (2006) Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm. J Clin Pharmacol 46:353-372. (Pubitemid 43260323)
16. Gerwins P, Sköldenberg E, and Claesson-Welsh L (2000) Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Critical Rev Oncol Hematol 34:185-194. (Pubitemid 30320963)
17. Glatt H, Boeing H, Engelke CE, Ma L, Kuhlow A, Pabel U, Pomplun D, Teubner W, and Meinl W (2001) Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat Res 482:27-40. (Pubitemid 32787079)
18. Glatt H, Engelke CE, Pabel U, Teubner W, Jones AL, Coughtrie MW, Andrae U, Falany CN, and Meinl W (2000) Sulfotransferases: genetics and role in toxicology. Toxicol Lett 112-113: 341-348. (Pubitemid 30138142)
19. Gong J, Gan J, Caceres-Cortes J, Christopher LJ, Arora V, Masson E, Williams D, Pursley J, Allentoff A, Lago M, et al. (2011) Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys and humans. Drug Metab Dispos 39:891-903.
20. Guengerich FP (2004) Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev 36:159-197.
21. Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611-650.
22. Herbst RS (2006) Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs 11:635-650.
23. Honma W, Shimada M, Sasano H, Ozawa S, Miyata M, Nagata K, Ikeda T, and Yamazoe Y (2002) Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 30:944-949. (Pubitemid 34815426)
24. Kiselyov A, Balakin KV, and Tkachenko SE (2007) VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 16:83-107. (Pubitemid 44964169)
25. Lamb DC, Waterman MR, Kelly SL, and Guengerich FP (2007) Cytochromes P450 and drug discovery. Curr Opin Biotechnol 18:504-512.
26. Lindsay J, Wang LL, Li Y, and Zhou SF (2008) Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 9:99-105. (Pubitemid 351460999)
27. Lu AY, Wang RW, and Lin JH (2003) Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 31:345-350. (Pubitemid 36378510)
28. Manetti F and Botta M (2003) Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK). Curr Pharm Des 9:567-581. (Pubitemid 36221724)
29. Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, and Fargnoli J (2009) Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother Pharmacol 65:55-66.
30. Mekhail T, Masson E, Fischer BS, Gong J, Iyer R, Gan J, Pursley J, Patricia D, Williams D, and Ganapathi R (2010) Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. Drug Metab Dispos 38:1962-1966.
31. Nishimura M and Naito S (2006) Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21:357-374.
32. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris R, Baudelet C, Walters I, et al. (2011) Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 17:1973-1983.
33. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
34. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and La Du BN (2002) Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30:488-493. (Pubitemid 34456967)
35. Tabata T, Katoh M, Tokudome S, Hosakawa M, Chiba K, Nakajima M, and Yokoi T (2004a) Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5′-deoxy-5-fluorocytidine formation. Drug Metab Dispos 32:762-767. (Pubitemid 38821879)
36. Tabata T, Katoh M, Tokudome S, Nakajima M, and Yokoi T (2004b) Identification of the cytolic carboxylesterase catalyzing the 5′-deoxy-5-fluorocytidine formation from capecitabine in human liver. Drug Metab Dispos 32:1103-1110. (Pubitemid 39287584)
37. Tassi E and Wellstein A. (2006) Tumor angiogenesis: initiation and targeting - therapeutic targeting of an FGF-binding protein, an angiogenic switch molecule, and indicator of early stages of gastrointestinal adenocarcinomas -. Cancer Res Treat 38:189-197.
38. Teubner W, Meinl W, Florian S, Kretzschmar M, and Glatt H (2007) Identification and localization of soluble sulfotransferases in the human gastrointestinal tract. Biochem J 404:207-215. (Pubitemid 46849592)
39. Underiner TL, Ruggeri B, and Gingrich DE (2004) Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem 11:731-745. (Pubitemid 38380047)
40. Xu G, Zhang W, Ma MK, and McLeod HL (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:2605-2611. (Pubitemid 34856347)
41. Zhang H, Davis CD, Sinz MW, and Rodrigues AD (2007) Cytochrome P450 reactionphenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667-687. (Pubitemid 351320636)